The investigation to end the COVID-19 continues.The ultimate goal is to find an antibody that will end this pandemic, the virus and all its variants that began in 2020 and that has taken the lives of millions of people.
Thus, a group of scientists from the Hospital of Lausana and the Federal Polytechnic School of that Swiss city (EPFL) have found a monoclonal antibody that neutralizes all the variants of the COVID-19.The discovery has been announced by scientists and published in Cell Reports magazine.
As explained, the antibody is able to block peak proteins and prevent lung cells from infecting.In this way, it stops the viral replica and facilitates the immune system to eliminate the COVID-19 of its body.The antibody is "one of the most powerful so far identified against the Coronavirus Sars-COV-2," EPFL said in a statement.
How to install linux on a chromebook and unlock its full potential http://t.co/dwdgnrlzrx (Will try This Soon, unless you talk me out of it)
— Brian Fiedler Fri Nov 15 19:02:18 +0000 2013
EPFL has also explained that the researchers designed this new antibody with the aim of having a "prolonged" duration in the human body.The duration of the developed antibody will be four to six months, while an unmodified antibody protects the patient for three to four weeks.“Thus, it becomes a very interesting preventive option to protect vulnerable not vaccinated or vaccinated people unable to produce an immune response;Immunodepressed people, people who have had an organ transplant and some cancer patients can protect themselves by injecting the antibody two or three times a year, ”says EPFL.
The finding has developed thanks to the isolation of lymphocytes of 40 patients with COVID-19.Three months after their infection, scientists extracted blood samples from eight of them with higher levels of antibody to produce monoclonal antibodies (MAB).The 10 mab with "greater affinity" for the 2019-Cov peak trimmer were kept for "an additional characterization," says Cell Reports.The clinical trials of a drug based on these antibodies will begin at the end of 2022.